Central Precocious Puberty – Management and Long-term Outcomes

Central precocious puberty (CPP) results from premature re-activation of the gonadotropic axis. CPP is much more common in girls than in boys and is idiopathic in most cases. In boys, precocious puberty is more likely to be linked to hypothalamic lesions (≈40%). Recent studies have implicated the in...

Descripción completa

Detalles Bibliográficos
Autores principales: Léger, Juliane, Carel, Jean-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2015
Materias:
Paediatric Endocrinology Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819064/
https://www.ncbi.nlm.nih.gov/pubmed/29632569
http://dx.doi.org/10.17925/EE.2015.11.01.45
_version_ 1783301131736186880
author Léger, Juliane
Carel, Jean-Claude
author_facet Léger, Juliane
Carel, Jean-Claude
author_sort Léger, Juliane
collection PubMed
description Central precocious puberty (CPP) results from premature re-activation of the gonadotropic axis. CPP is much more common in girls than in boys and is idiopathic in most cases. In boys, precocious puberty is more likely to be linked to hypothalamic lesions (≈40%). Recent studies have implicated the inactivation of MKRN3 gene in ‘idiopathic’ CPP Gonadotropin-releasing hormone agonists are the standard treatment for progressive CPP.
format Online
Article
Text
id pubmed-5819064
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Touch Medical Media
record_format MEDLINE/PubMed
spelling pubmed-58190642018-04-09 Central Precocious Puberty – Management and Long-term Outcomes Léger, Juliane Carel, Jean-Claude Eur Endocrinol Paediatric Endocrinology Editorial Central precocious puberty (CPP) results from premature re-activation of the gonadotropic axis. CPP is much more common in girls than in boys and is idiopathic in most cases. In boys, precocious puberty is more likely to be linked to hypothalamic lesions (≈40%). Recent studies have implicated the inactivation of MKRN3 gene in ‘idiopathic’ CPP Gonadotropin-releasing hormone agonists are the standard treatment for progressive CPP. Touch Medical Media 2015-04 2015-04-11 /pmc/articles/PMC5819064/ /pubmed/29632569 http://dx.doi.org/10.17925/EE.2015.11.01.45 Text en © The Author(s) 2015 http://creativecommons.org/licenses/by/2.5/ This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
spellingShingle Paediatric Endocrinology Editorial
Léger, Juliane
Carel, Jean-Claude
Central Precocious Puberty – Management and Long-term Outcomes
title Central Precocious Puberty – Management and Long-term Outcomes
title_full Central Precocious Puberty – Management and Long-term Outcomes
title_fullStr Central Precocious Puberty – Management and Long-term Outcomes
title_full_unstemmed Central Precocious Puberty – Management and Long-term Outcomes
title_short Central Precocious Puberty – Management and Long-term Outcomes
title_sort central precocious puberty – management and long-term outcomes
topic Paediatric Endocrinology Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819064/
https://www.ncbi.nlm.nih.gov/pubmed/29632569
http://dx.doi.org/10.17925/EE.2015.11.01.45
work_keys_str_mv AT legerjuliane centralprecociouspubertymanagementandlongtermoutcomes
AT careljeanclaude centralprecociouspubertymanagementandlongtermoutcomes

Ejemplares similares